$1.400
-0.029 (-2.10%)At close
OKYO Comparative Benchmarking
In the context of the broader market, OKYO competes directly with industry leaders such as CNXU and QUCY. With a market capitalization of $73.47M, it holds a leading position in the sector. When comparing efficiency, OKYO's gross margin of N/A stands against CNXU's N/A and QUCY's N/A. Such benchmarking helps identify whether OKYO Pharma Ltd is trading at a premium or discount relative to its financial performance.
OKYO Pharma Ltd Financial Performance
The company's current ratio stands at 0.40, indicating liquidity issues, and it has reported negative net income for the last two quarters, with a net loss of $2,026,474 in Q1 2026. However, total equity is projected to turn positive in Q1 2027, suggesting potential recovery.
Financials
Related articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.